As disease recurrences occur later for ER+/PR±/HER2+ BC, regardless of treatment with anti-HER2 therapy (as previously argued), we hypothesize that patients in this subgroup have not yet fully matured all their relapse events, also considering that they received endocrine therapy, with its abovementioned carry-over effect. The gene discussed is ESR1; the disease is breast cancer.